Biosplice Therapeutics Submits NDA for First-in-Class Knee Osteoarthritis Drug Lorecivivint

Biosplice Therapeutics has shared an update.

The company announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for lorecivivint (LOR), a potential first-in-class therapy for knee osteoarthritis that aims both to relieve pain and modify disease progression. The NDA is supported by more than a decade of research and data from 11 clinical studies involving over 1,800 patients.

For investors, the NDA submission represents a key regulatory inflection point that could materially affect Biosplice Therapeutics’ valuation and future revenue prospects if the therapy is approved. A successful approval would position the company in a large and growing osteoarthritis market with substantial unmet medical need, potentially providing a differentiated product profile versus existing symptomatic treatments. However, regulatory risk remains significant at this stage, as the FDA’s review will scrutinize both safety and efficacy claims, including the disease-modifying potential highlighted by the company. The outcome and timing of the FDA review, as well as any requirements for additional data, will be critical determinants of the company’s commercialization timeline, partnering opportunities, and competitive standing within the osteoarthritis and broader musculoskeletal therapeutics segment.